Evidence map›Paper›PMID 35954490›Full record

ArticleCancers2022

A New Clinical Instrument for Estimating the Ambulatory Status after Irradiation for Malignant Spinal Cord Compression.

Dirk Rades, Ahmed Al-Salool, Christian Staackmann, Florian Cremers, Jon Cacicedo, Darejan Lomidze, Barbara Segedin, Blaz Groselj, Natalia Jankarashvili, Antonio J Conde-Moreno and 3 more

Open access · goldAbstract read
In one paragraph

Article in Cancers, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.5field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. The effect of hypersensitive C-reactive protein to albumin ratio on the risk of fragility fracture in the Chinese male population.Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2025
    Article
  3. Review
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 8 institutions in 6 countries.

Dirk RadesDepartment of Radiation Oncology, University of Lubeck, 23562 Lubeck, Germany.
Ahmed Al-SaloolDepartment of Radiation Oncology, University of Lubeck, 23562 Lubeck, Germany.
Christian StaackmannDepartment of Radiation Oncology, University of Lubeck, 23562 Lubeck, Germany.
Florian CremersDepartment of Radiation Oncology, University of Lubeck, 23562 Lubeck, Germany.
Jon CacicedoDepartment of Radiation Oncology, Cruces University Hospital/Biocruces Health Research Institute, 48903 Barakaldo, Spain.
Darejan LomidzeRadiation Oncology Department, Tbilisi State Medical University and Ingorokva High Medical Technology University Clinic, Tbilisi 0177, Georgia.
Barbara SegedinDepartment of Radiotherapy, Institute of Oncology Ljubljana and Faculty of Medicine, University of Ljubljana, 1000 Ljubljana, Slovenia.
Blaz GroseljDepartment of Radiotherapy, Institute of Oncology Ljubljana and Faculty of Medicine, University of Ljubljana, 1000 Ljubljana, Slovenia.
Natalia JankarashviliDepartment of Radiation Oncology, Acad. F. Todua Medical Center-Research Institute of Clinical Medicine, Tbilisi 0112, Georgia.ORCID 0000-0003-2123-9873
Antonio J Conde-MorenoDepartment of Radiation Oncology, University and Polytechnic Hospital La Fe, 46026 Valencia, Spain.
Raquel CiervideDepartment of Radiation Oncology, University Hospital HM Hospitales, Sanchinarro, 28050 Madrid, Spain.ORCID 0000-0003-0130-878X
Charlotte KristiansenDepartment of Oncology, Vejle Hospital, University Hospital of Southern Denmark, 7100 Vejle, Denmark.ORCID 0000-0002-8073-5781
Steven E SchildDepartment of Radiation Oncology, Mayo Clinic, Scottsdale, AZ 85259, USA.
University of Lübeck · DEUniversity of Ljubljana · SIBioCruces Health research Institute · ESHM Hospitales · ESHospital Universitari i Politècnic La Fe · ESMayo Clinic in Arizona · USTbilisi State Medical University · GEVejle Sygehus · DK

Funding

European Regional Development Fund (Interreg Deutschland-Danmark program) 094 -1.1-18
6 · The paper itself

Abstract

Estimating post-treatment ambulatory status can improve treatment personalization of patients irradiated for malignant spinal cord compression (MSCC). A new clinical score was developed from data of 283 patients treated with radiotherapy alone in prospective trials. Radiotherapy regimen, age, gender, tumor type, interval from tumor diagnosis to MSCC, number of affected vertebrae, other bone metastases, visceral metastases, time developing motor deficits, ambulatory status, performance score, sensory deficits, and sphincter dysfunction were evaluated. For factors with prognostic relevance in the multivariable logistic regression model after backward stepwise variable selection, scoring points were calculated (post-radiotherapy ambulatory rate in % divided by 10) and added for each patient. Four factors (primary tumor type, sensory deficits, sphincter dysfunction, ambulatory status) were used for the instrument that includes three prognostic groups (17-21, 22-31, and 32-37 points). Post-radiotherapy ambulatory rates were 10%, 65%, and 97%, respectively, and 2-year local control rates were 100%, 75%, and 88%, respectively. Positive predictive values to predict ambulatory and non-ambulatory status were 97% and 90% using the new score, and 98% and 79% using the previous instrument. The new score appeared more precise in predicting non-ambulatory status. Since patients with 32-37 points had high post-radiotherapy ambulatory and local control rates, they may not require surgery.

Indexed as

ambulatory statusirradiationmalignant spinal cord compressionprognostic instrumentprospective trials

Identifiers

PMID35954490
PMCPMC9367288
OpenAlexW4290466963

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.